Samreen Ahmed
Overview
Explore the profile of Samreen Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
990
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Robertson J, Coleman R, Cheung K, Evans A, Holcombe C, Skene A, et al.
Clin Cancer Res
. 2022 Dec;
28(24):5469.
PMID: 36519303
No abstract available.
12.
Brahmer J, Lee J, Ciuleanu T, Bernabe Caro R, Nishio M, Urban L, et al.
J Clin Oncol
. 2022 Oct;
41(6):1200-1212.
PMID: 36223558
Purpose: We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non-small-cell lung cancer, regardless of...
13.
Navani N, Butler R, Ibrahimo S, Verma A, Evans M, Doherty G, et al.
Lung Cancer
. 2022 Sep;
172:142-153.
PMID: 36099709
Targeted therapy against actionable variants has revolutionised the treatment landscape for non-small cell lung cancer (NSCLC). Approximately half of NSCLC adenocarcinomas have an actionable variant, making molecular testing a critical...
14.
Anusheel , Benitez J, Jaka S, Roshan N, Kommuru S, Ahmed S, et al.
Cureus
. 2022 Sep;
14(7):e27435.
PMID: 36053247
Objectives To evaluate the risk factors and hospitalization outcomes for cerebrovascular diseases (CVD) in patients with vasculitis. Methods We conducted a cross-sectional study using the Nationwide Inpatient Sample (NIS), 2019....
15.
Kaur M, Ahmed S, Younis H, Jaka S, Anusheel , Benitez J, et al.
Cureus
. 2022 Sep;
14(7):e27354.
PMID: 36048422
Objectives To evaluate the demographic and comorbid risk factors for cerebrovascular disease (CVD) hospitalization in patients with retinal artery occlusion (RAO) and study the impact on hospitalization outcomes. Methods We...
16.
Jafri M, Kristeleit H, Misra V, Baxter M, Ahmed S, Jegannathen A, et al.
Oncology
. 2022 Aug;
100(12):666-673.
PMID: 36044833
Introduction: This study examined real-world data from patients who received eribulin for metastatic breast cancer (MBC) collected from 14 hospitals across the UK. Methods: Anonymized data were collected retrospectively from...
17.
Woll P, Gaunt P, Danson S, Steele N, Ahmed S, Mulatero C, et al.
Lung Cancer
. 2022 Jul;
171:26-33.
PMID: 35872530
Objectives: Small cell lung cancer (SCLC) responds well to chemoradiotherapy but frequently relapses. Here, we evaluate activity and safety of the poly (adenosine diphosphate (ADP)-ribose) polymerase (PARP) inhibitor olaparib as...
18.
Park S, Bennett-Baker P, Ahmed S, Arlt M, Ljungman M, Glover T, et al.
Nucleic Acids Res
. 2021 Jun;
49(13):7507-7524.
PMID: 34181717
Impaired replication progression leads to de novo copy number variant (CNV) formation at common fragile sites (CFSs). We previously showed that these hotspots for genome instability reside in late-replicating domains...
19.
Vagts C, Ascoli C, Fraidenburg D, Baughman R, Huang Y, Edafetanure-Ibeh R, et al.
Front Med (Lausanne)
. 2021 Mar;
8:595077.
PMID: 33718397
Sarcoidosis is a T-helper cell mediated disease characterized by granulomatous inflammation. We posited that unsupervised clustering of various features in sarcoidosis would establish phenotypes associated with inflammatory activity measured by...
20.
Reck M, Ciuleanu T, Lee J, Schenker M, Audigier-Valette C, Zurawski B, et al.
J Thorac Oncol
. 2021 Jan;
16(4):665-676.
PMID: 33485960
Introduction: In CheckMate 227 (NCT02477826), patients with treatment-naive stage IV or recurrent NSCLC and 1% or greater tumor programmed death ligand 1 expression had significantly improved overall survival with nivolumab...